Mustafa Kemal Balci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5503648/publications.pdf

Version: 2024-02-01

58 papers

6,733 citations

279798 23 h-index 55 g-index

60 all docs 60 docs citations

60 times ranked

8188 citing authors

#	Article	IF	CITATIONS
1	Identifying Clinical Characteristics of Hypoparathyroidism in Turkey: HIPOPARATURK-NET Study. Calcified Tissue International, 2022, 110, 204-214.	3.1	4
2	Clinical Characteristics and Follow-Up Results of Adrenal Incidentaloma. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 349-356.	1.2	18
3	Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes. Molecular Therapy, 2021, 29, 149-161.	8.2	10
4	Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation. Gene Therapy, 2021, 28, 130-141.	4.5	9
5	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study). Lipids in Health and Disease, 2020, 19, 237.	3.0	8
6	Cytopathology-histopathology correlation and the effect of nodule diameter on diagnostic performance in patients undergoing thyroid fine-needle aspiration biopsy. Journal of Cancer Research and Therapeutics, 2020, 16, 53.	0.9	2
7	Diagnostic value of the late-night salivary cortisol in the diagnosis of clinical and subclinical Cushing's syndrome: results of a single-center 7-year experience. Journal of Investigative Medicine, 2019, 67, 28-33.	1.6	5
8	Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role intreatment; from the past to future. World Journal of Diabetes, 2019, 10, 446-453.	3.5	17
9	Therapeutic Potential of Lentivirus-Mediated Glucagon-Like Peptide-1 Gene Therapy for Diabetes. Human Gene Therapy, 2018, 29, 802-815.	2.7	16
10	Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study). Diabetes Research and Clinical Practice, 2018, 146, 138-147.	2.8	25
11	Cystic lateral neck mass. Journal of Cancer Research and Therapeutics, 2018, 14, 1437-1438.	0.9	7
12	Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations. Turkish Journal of Endocrinology and Metabolism, 2018, 22, 183-197.	0.5	1
13	Generation of a Novel Gene Therapy Vector Encoding Beta-Cell–Specific Insulin for Diabetes Treatment. Diabetes, 2018, 67, 1780-P.	0.6	0
14	Bone metastases without primary tumor. Journal of Cancer Research and Therapeutics, 2018, 14, 447-450.	0.9	4
15	Evaluation of Incidental Thyroid Nodules in Cancer Patients. Journal of the National Medical Association, 2017, 109, 299-306.	0.8	2
16	Which type 2 diabetes mellitus patients should be screened for subclinical Cushing's syndrome?. Hormones, 2017, 16, 22-32.	1.9	6
17	Cardiovascular Risk Factor Control Ratios in Turkey: The results of SURF (SUrvey of Risk Factor) Tj ETQq1 1 0.784 Dernegi Arsivi, 2017, 45, 398-407.	4314 rgBT 0.5	Overlock 10
18	Parathyroidectomy in asymptomatic primary hyperparathyroidism reduces carotid intimaâ€media thickness and arterial stiffness. Clinical Endocrinology, 2016, 84, 39-47.	2.4	32

#	Article	IF	Citations
19	The effects of hyperventilation on axonal excitability parameters in patients with diabetes mellitus and polyneuropathy. Diabetes Research and Clinical Practice, 2016, 118, 112-120.	2.8	1
20	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 311-322.	27.0	5,070
21	<scp>LEADER</scp> 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the <scp>L</scp> iraglutide <scp>E</scp> ffect and <scp>A</scp> ction in <scp>D</scp> iabetes: <scp>E</scp> valuation of cardiovascular outcome <scp>R</scp> esults (<scp>LEADER</scp>) trial: preliminary observations. Diabetes. Obesity and Metabolism, 2015, 17, 477-486.	4.4	18
22	Insulin degludec improves longâ€term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basalâ€bolus insulin therapy. Diabetes, Obesity and Metabolism, 2015, 17, 202-206.	4.4	32
23	Incretins: Their physiology and application in the treatment of diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2014, 30, 354-371.	4.0	84
24	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal, 2013, 166, 823-830.e5.	2.7	182
25	Clinical utility of insulin and insulin analogs. Islets, 2013, 5, 67-78.	1.8	40
26	Therapeutic potential of VIP vs PACAP in diabetes. Journal of Molecular Endocrinology, 2012, 49, R157-R167.	2.5	41
27	Insulin gene therapy from design to beta cell generation. Expert Reviews in Molecular Medicine, 2012, 14, e18.	3.9	12
28	Subcutaneous NPH Insulin for Severe Hypertriglyceridemia in a Pregnant Patient with Type V Hyperlipoproteinemia: a Case Report. Balkan Medical Journal, 2012, 29, 222-224.	0.8	2
29	TRAIL and DcR1 Expressions Are Differentially Regulated in the Pancreatic Islets of STZ- versus CY-Applied NOD Mice. Experimental Diabetes Research, 2011, 2011, 1-11.	3.8	10
30	The metabolic profile in patients with skin tags. Clinical and Experimental Medicine, 2010, 10, 193-197.	3.6	63
31	The Relationship Between Plasma Leptin Levels and Chronic Complication in Patients with Type 2 Diabetes Mellitus. Metabolic Syndrome and Related Disorders, 2010, 8, 499-503.	1.3	22
32	The prevalence of non-classic adrenal hyperplasia among Turkish women with hyperandrogenism. Gynecological Endocrinology, 2010, 26, 139-143.	1.7	24
33	Adenovirus-Mediated TRAIL Gene (Ad5hTRAIL) Delivery into Pancreatic Islets Prolongs Normoglycemia in Streptozotocin-Induced Diabetic Rats. Human Gene Therapy, 2009, 20, 1177-1189.	2.7	31
34	Isokinetic evaluation of muscle strength in patients with thyroid dysfunction. Isokinetics and Exercise Science, 2009, 17, 69-72.	0.4	1
35	High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients. Pancreas, 2009, 38, 154-160.	1.1	30
36	Molecular mechanisms of death ligandâ€mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes. Journal of Cellular Biochemistry, 2008, 104, 710-720.	2.6	27

#	Article	IF	Citations
37	Gibberellic acid, a plant growth regulator, increases mast cell recruitment and alters Substance P levels. Toxicology, 2008, 254, 75-81.	4.2	28
38	THE EFFECTS OF PLANT GROWTH FACTOR GIBBERELLIC ACID ON MAST CELL DEGRANULATION AND SUBSTANCE P LEVELS. Atherosclerosis Supplements, 2008, 9, 134.	1.2	0
39	The Effect of Thyroid Gland Palpation and Fine Needle Aspiration Biopsy on Serum Thyroid Hormoneand Thyroglobulin Levels. , 2008, 18, 238-240.		2
40	High Levels of Endogenous Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression Correlate With Increased Cell Death in Human Pancreas. Pancreas, 2008, 36, 385-393.	1.1	27
41	Incidental Thyroid Carcinoma in Thyrotoxic Patients Treated by Surgery. Hormone Research in Paediatrics, 2007, 67, 96-99.	1.8	21
42	Acute Effect of Exercise on Plasma Leptin Level and Insulin Resistance in Obese Women with Stable Caloric Intake. Endocrine Research, 2007, 32, 9-17.	1.2	29
43	Relationship between weight loss and gallbladder motility in obese women. Journal of the National Medical Association, 2006, 98, 1670-6.	0.8	3
44	Effects of exercise on gallbladder volume and motility in obese women. Journal of Clinical Ultrasound, 2005, 33, 218-222.	0.8	12
45	Insulin resistance in chronic hepatitis C. International Journal of Clinical Practice, 2004, 58, 1020-1022.	1.7	24
46	Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. International Journal of Obesity, 2004, 28, 1059-1063.	3.4	22
47	The Effects of Diet, Sulfonylurea, and Repaglinide Therapy on Clinical and Metabolic Parameters in Type 2 Diabetic Patients During Ramadan. Endocrine Research, 2004, 30, 169-177.	1.2	79
48	Comparison of Efficacy of Sibutramine or Orlistat Versus Their Combination in Obese Women. Endocrine Research, 2004, 30, 159-167.	1.2	42
49	Sonographic evaluation of gallbladder volume and ejection fraction in obese women without gallstones. Journal of Clinical Ultrasound, 2003, 31, 352-357.	0.8	26
50	Musculoskeletal manifestations in patients with thyroid disease. Clinical Endocrinology, 2003, 59, 162-167.	2.4	157
51	The effect of body weight and weight loss on thyroid volume and function in obese women. Clinical Endocrinology, 2003, 59, 258-262.	2.4	147
52	Hypocalcemic Cardiomyopathy due to Untreated Hypoparathyroidism. Hormone Research in Paediatrics, 2003, 59, 201-204.	1.8	23
53	No Effect of Simvastatin Treatment on Insulin Sensitivity in Patients with Primary Hypercholesterolemia. Endocrine Research, 2003, 29, 265-275.	1.2	18
54	Medullary Thyroid Carcinoma, Follicular Variant. Endocrine Pathology, 2002, 13, 75-80.	9.0	12

#	Article	IF	CITATIONS
55	Serum HbA _{1c} Levels and Exercise Capacity in Diabetic Patients . International Heart Journal, 2001, 42, 607-616.	0.6	26
56	Shoulder Adhesive Capsulitis and Shoulder Range of Motion in Type II Diabetes Mellitus. Journal of Diabetes and Its Complications, 1999, 13, 135-140.	2.3	162
57	The Characteristics of Nine Patients with Adrenal Incidentalomas Endocrine Journal, 1995, 42, 497-503.	1.6	3
58	Choriocarcinoma Metastasis in the Thyroid Gland. Thyroid, 1994, 4, 301-303.	4. 5	13